Biogen Inc
NASDAQ:BIIB
Intrinsic Value
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. [ Read More ]
The intrinsic value of one BIIB stock under the Base Case scenario is 217.7 USD. Compared to the current market price of 202.46 USD, Biogen Inc is Undervalued by 7%.
Valuation Backtest
Biogen Inc
Run backtest to discover the historical profit from buying and selling BIIB stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Biogen Inc
Current Assets | 6.9B |
Cash & Short-Term Investments | 1B |
Receivables | 2.1B |
Other Current Assets | 3.7B |
Non-Current Assets | 20B |
Long-Term Investments | 745m |
PP&E | 3.7B |
Intangibles | 14.6B |
Other Non-Current Assets | 928.6m |
Current Liabilities | 3.4B |
Accounts Payable | 403.3m |
Accrued Liabilities | 1.7B |
Other Current Liabilities | 1.4B |
Non-Current Liabilities | 8.6B |
Long-Term Debt | 6.8B |
Other Non-Current Liabilities | 1.8B |
Earnings Waterfall
Biogen Inc
Revenue
|
9.8B
USD
|
Cost of Revenue
|
-2.5B
USD
|
Gross Profit
|
7.3B
USD
|
Operating Expenses
|
-5.3B
USD
|
Operating Income
|
2B
USD
|
Other Expenses
|
-888.8m
USD
|
Net Income
|
1.2B
USD
|
Free Cash Flow Analysis
Biogen Inc
BIIB Profitability Score
Profitability Due Diligence
Biogen Inc's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
Score
Biogen Inc's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
BIIB Solvency Score
Solvency Due Diligence
Biogen Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Score
Biogen Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BIIB Price Targets Summary
Biogen Inc
According to Wall Street analysts, the average 1-year price target for BIIB is 306.71 USD with a low forecast of 217.15 USD and a high forecast of 525 USD.
Ownership
BIIB Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
BIIB Price
Biogen Inc
Average Annual Return | 5.59% |
Standard Deviation of Annual Returns | 18.97% |
Max Drawdown | -55% |
Market Capitalization | 29.3B USD |
Shares Outstanding | 145 700 000 |
Percentage of Shares Shorted | 2.76% |
BIIB News
Last Important Events
Biogen Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Biogen Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 9,610 full-time employees. The company is focused on discovering, developing and delivering therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. The company has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA) and Alzheimer's disease. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. The company also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA; OCREVUS; and other potential anti-CD20 therapies, including mosunetuzumab.
Contact
IPO
Employees
Officers
The intrinsic value of one BIIB stock under the Base Case scenario is 217.7 USD.
Compared to the current market price of 202.46 USD, Biogen Inc is Undervalued by 7%.